GLP-1 weight loss injections

GLP-1 agonists for weight loss, diabetes, sleep apnea, and W8MD medical weight loss programs

GLP-1 agonists
Before and after weight loss pictures
Trade names	Wegovy, Ozempic, Rybelsus, Zepbound, Mounjaro, Saxenda, Victoza, Trulicity
Generic name	Semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide
Drug class	GLP-1 receptor agonist, incretin mimetic, anti-obesity medication, diabetes medication
Routes of administration	Subcutaneous injection; oral formulation available for selected semaglutide products
Uses	Weight loss, obesity, type 2 diabetes, cardiovascular risk reduction in selected patients, obstructive sleep apnea in selected adults with obesity using Zepbound
Mechanism of action	Appetite reduction, delayed gastric emptying, increased glucose-dependent insulin secretion, reduced glucagon secretion, improved satiety
Related drugs	GLP-1, GIP, glucagon, semaglutide, tirzepatide, liraglutide, retatrutide

GLP-1 weight loss injections may help selected patients reduce appetite, improve satiety, lose weight, and improve obesity-related health conditions.

W8MD Weight Loss, Sleep and MedSpa can evaluate patients for GLP-1 weight loss medications when medically appropriate.

GLP-1 medications work best when combined with nutrition, protein planning, physical activity, sleep optimization, and long-term maintenance.

GLP-1 agonists, also called GLP-1 receptor agonists or incretin-based medications, are a class of medications that mimic or activate the effects of glucagon-like peptide-1 or related gut hormones involved in appetite, blood sugar regulation, insulin secretion, gastric emptying, and satiety. They are used in the treatment of type 2 diabetes, obesity, overweight with weight-related medical problems, and selected cardiometabolic conditions.

Important GLP-1 and related medications include semaglutide, liraglutide, tirzepatide, dulaglutide, exenatide, and lixisenatide. Common brand names include Wegovy, Ozempic, Rybelsus, Saxenda, Victoza, Zepbound, Mounjaro, and Trulicity. Newer investigational agents include retatrutide, a triple-receptor agonist targeting GIP, GLP-1, and glucagon receptors.

W8MD Weight Loss, Sleep and MedSpa Centers can help eligible patients access physician-supervised GLP-1 weight loss injections such as Wegovy, Ozempic, Zepbound, Mounjaro, semaglutide, and tirzepatide when medically appropriate. W8MD also helps patients combine these medications with medical weight loss, nutrition, meal replacements, low-carbohydrate diet planning, sleep apnea evaluation, and long-term weight loss maintenance.

Overview

GLP-1 agonists are not simply “diet shots.” They are medical treatments that affect appetite, satiety, glucose regulation, digestion, and body weight. They should be used under medical supervision, especially in patients with diabetes, high blood pressure, kidney disease, gastrointestinal disorders, gallbladder disease, pancreatitis history, pregnancy considerations, or other medical problems.

GLP-1 medications may help with:

• Weight loss
• Reduced appetite
• Improved satiety
• Lower hemoglobin A1c
• Improved insulin resistance
• Reduced food cravings in some patients
• Improved cardiometabolic risk
• Reduced triglycerides in some patients
• Improved fatty liver disease risk factors in some patients
• Reduced sleep apnea severity in selected patients with obesity
• Long-term weight maintenance when continued and monitored

What is GLP-1?

GLP-1, or glucagon-like peptide-1, is a hormone released from the gut after eating. It helps regulate appetite and blood sugar.

GLP-1 actions include:

• Increasing glucose-dependent insulin secretion
• Reducing glucagon secretion when glucose is high
• Slowing gastric emptying
• Increasing fullness
• Reducing appetite
• Supporting post-meal blood sugar control

How GLP-1 agonists work

GLP-1 agonists bind to GLP-1 receptors and extend the effects of natural GLP-1. Because natural GLP-1 is broken down quickly, medication versions are modified to last longer.

They may promote weight loss through:

• Reduced appetite
• Increased satiety
• Smaller meal size
• Reduced snacking
• Delayed gastric emptying
• Improved blood sugar control
• Reduced food reward in some patients
• Improved insulin sensitivity indirectly through weight loss

GLP-1 agonists and weight loss

GLP-1 medications are widely used in medical weight loss because they address appetite biology, not just willpower. Many patients with obesity, insulin resistance, prediabetes, PCOS, metabolic syndrome, fatty liver disease, and sleep apnea struggle with hunger, cravings, and weight regain. GLP-1-based therapy can help selected patients reduce calorie intake and improve adherence to a structured plan.

A successful GLP-1 weight-loss program should include:

• Medical evaluation
• BMI and weight-history review
• Medication review
• Nutrition planning
• Protein intake support
• Hydration
• Physical activity
• Resistance training
• Monitoring for side effects
• Sleep apnea screening when appropriate
• Long-term maintenance planning

FDA-approved GLP-1 and related medications

Semaglutide

Semaglutide is a GLP-1 receptor agonist used in several products.

Common semaglutide brands include:

• Wegovy - used for chronic weight management and selected cardiovascular risk reduction indications
• Ozempic - used for type 2 diabetes
• Rybelsus - oral semaglutide used for type 2 diabetes

The FDA approved Wegovy for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and in 2024 approved Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight(link). U.S. Food and Drug Administration.March 8, 2024. DailyMed describes Wegovy as semaglutide injection, a human GLP-1 receptor agonist or GLP-1 analog.WEGOVY - semaglutide injection, solution(link). DailyMed, National Library of Medicine.

Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates both glucose-dependent insulinotropic polypeptide receptors and GLP-1 receptors.

Common tirzepatide brands include:

• Zepbound - used for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity
• Mounjaro - used for type 2 diabetes

DailyMed describes Zepbound as tirzepatide injection containing tirzepatide, a GIP receptor and GLP-1 receptor agonist.ZEPBOUND - tirzepatide injection, solution(link). DailyMed, National Library of Medicine.

Liraglutide

Liraglutide is an older GLP-1 receptor agonist.

Common liraglutide brands include:

• Saxenda - used for chronic weight management
• Victoza - used for type 2 diabetes

Liraglutide is typically administered once daily, unlike many newer GLP-1-based medications that are administered once weekly.

Dulaglutide

Dulaglutide, sold as Trulicity, is a once-weekly GLP-1 receptor agonist used for type 2 diabetes. It is not primarily a weight-loss medication, but weight changes may occur in some patients.

Exenatide

Exenatide is an earlier GLP-1 receptor agonist used for type 2 diabetes. It has been marketed as Byetta and Bydureon.

Lixisenatide

Lixisenatide is a GLP-1 receptor agonist used for type 2 diabetes and has been marketed as Adlyxin.

Emerging GLP-1 and related medications

Retatrutide

Retatrutide is an investigational triple-hormone-receptor agonist that targets GIP, GLP-1, and glucagon receptors. It is sometimes misspelled as “ritatrutide.” Retatrutide is not yet an FDA-approved medication for weight loss, but it has shown promising results in clinical trials.

A phase 2 trial published in the New England Journal of Medicine reported that once-weekly retatrutide produced substantial weight reduction at 24 and 48 weeks, with dose-dependent efficacy, and the authors concluded that the findings supported further phase 3 investigation."Triple-Hormone-Receptor Agonist Retatrutide for Obesity".New England Journal of Medicine.2023;doi:10.1056/NEJMoa2301972.PMID:37366315.

Because retatrutide remains investigational, patients should not purchase research peptides, online “retatrutide,” or unapproved products marketed for human use. Such products may be unsafe, unregulated, counterfeit, contaminated, or incorrectly dosed.

Orforglipron

Orforglipron is an investigational oral non-peptide GLP-1 receptor agonist being studied for obesity and type 2 diabetes. If approved in the future, oral GLP-1 options may expand treatment choices for patients who prefer tablets over injections.

CagriSema

CagriSema is an investigational combination of cagrilintide and semaglutide being studied for obesity. Cagrilintide is an amylin analog, while semaglutide is a GLP-1 receptor agonist.

Other pipeline agents

Other investigational agents may target multiple hormonal pathways, including GLP-1, GIP, glucagon, amylin, and other appetite and metabolic signaling systems.

Comparison of selected GLP-1 and related medications

Medication	Brand names	Main receptor action	Common use	Status
Semaglutide	Wegovy, Ozempic, Rybelsus	GLP-1 receptor agonist	Weight management, type 2 diabetes, selected cardiovascular risk reduction	FDA-approved for selected uses
Tirzepatide	Zepbound, Mounjaro	GIP and GLP-1 receptor agonist	Weight management, type 2 diabetes, moderate-to-severe OSA in adults with obesity using Zepbound	FDA-approved for selected uses
Liraglutide	Saxenda, Victoza	GLP-1 receptor agonist	Weight management, type 2 diabetes	FDA-approved for selected uses
Dulaglutide	Trulicity	GLP-1 receptor agonist	Type 2 diabetes	FDA-approved
Exenatide	Byetta, Bydureon	GLP-1 receptor agonist	Type 2 diabetes	FDA-approved
Lixisenatide	Adlyxin	GLP-1 receptor agonist	Type 2 diabetes	FDA-approved
Retatrutide	Investigational	GIP, GLP-1, and glucagon receptor agonist	Obesity research	Investigational, not FDA-approved

Brand names and common confusion

Patients often confuse brand names and generic names.

Generic name	Weight-loss brand	Diabetes brand	Notes
Semaglutide	Wegovy	Ozempic, Rybelsus	Wegovy is used for weight management; Ozempic and Rybelsus are diabetes brands
Tirzepatide	Zepbound	Mounjaro	Zepbound is used for weight management and moderate-to-severe OSA in adults with obesity; Mounjaro is a diabetes brand
Liraglutide	Saxenda	Victoza	Saxenda is a daily injection for weight management

Zepbound and obstructive sleep apnea

Zepbound is important for W8MD because it can connect medical weight loss and sleep medicine. In December 2024, the FDA approved Zepbound as the first medication for moderate-to-severe obstructive sleep apnea in adults with obesity.FDA Approves First Medication for Obstructive Sleep Apnea(link). U.S. Food and Drug Administration.December 20, 2024.

The FDA stated that Zepbound’s approval was based on two randomized, double-blind, placebo-controlled studies in adults with moderate-to-severe OSA and obesity, including one study in patients using positive airway pressure and one in patients unable or unwilling to use it.FDA Approves First Medication for Obstructive Sleep Apnea(link). U.S. Food and Drug Administration.December 20, 2024.

Who may qualify for GLP-1 weight loss medications?

Eligibility depends on medical history, BMI, insurance requirements, medication availability, contraindications, and clinician judgment. Many weight-loss medication guidelines use criteria such as:

• BMI of 30 or higher
• BMI of 27 or higher with weight-related medical conditions
• Hypertension
• Prediabetes
• Type 2 diabetes
• Dyslipidemia
• Sleep apnea
• Fatty liver disease
• PCOS
• Metabolic syndrome

Final eligibility should be determined by a qualified healthcare provider.

Common side effects

Common GLP-1 and related medication side effects may include:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal discomfort
• Heartburn
• Reduced appetite
• Bloating
• Injection-site reactions
• Fatigue in some patients

Side effects often occur during dose escalation and may improve with slower eating, smaller portions, lower-fat meals, hydration, and medical dose adjustment.

Important warnings and precautions

GLP-1 and related medications are not appropriate for everyone. DailyMed labeling for Wegovy includes a boxed warning about thyroid C-cell tumors observed in rodents and states that it is unknown whether semaglutide causes medullary thyroid carcinoma in humans.WEGOVY - semaglutide injection, solution(link). DailyMed, National Library of Medicine.

Patients should discuss risks with a healthcare provider, especially if they have:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Pancreatitis history
• Gallbladder disease
• Severe gastrointestinal disease
• Kidney disease
• Pregnancy or plans for pregnancy
• Breastfeeding
• Eating disorder history
• Use of insulin or sulfonylureas
• Dehydration risk

Nutrition while using GLP-1 medications

GLP-1 medications reduce appetite, but nutrition quality remains essential. Patients may eat less, so every meal should count.

W8MD may advise patients to focus on:

• Protein-first meals
• Smaller portions
• Hydration
• Fiber as tolerated
• Non-starchy vegetables
• Avoiding greasy meals if nausea occurs
• Avoiding sugary drinks
• Avoiding overeating despite fullness
• Resistance training
• Electrolytes when appropriate
• Long-term maintenance planning

Muscle preservation

Weight loss can include both fat loss and lean mass loss. GLP-1 patients should protect muscle through:

• Adequate protein
• Strength training
• Resistance exercises
• Hydration
• Sleep quality
• Avoiding excessive calorie restriction
• Medical monitoring

W8MD affordable GLP-1 weight loss options

W8MD Weight Loss, Sleep and MedSpa Centers offer physician-supervised GLP-1 weight-loss care for eligible patients in New York City, Brooklyn, New Jersey, Philadelphia, and the Greater Philadelphia area.

W8MD may help eligible patients with:

• GLP-1 weight loss injections
• Wegovy
• Ozempic
• Zepbound
• Mounjaro
• Semaglutide
• Tirzepatide
• Liraglutide
• Saxenda
• Traditional diet pills
• Meal replacements
• Low-carbohydrate diet
• Ketogenic diet
• Sleep apnea evaluation
• Long-term weight loss maintenance

Limited-time W8MD GLP-1 special

Affordable GLP-1 weight loss shots - limited time special

W8MD offers GLP-1 weight loss injections such as Wegovy, Ozempic, Zepbound, Mounjaro, semaglutide, and tirzepatide when medically appropriate.

• Affordable GLP-1 options starting at $29.99/week and up with insurance for visits for eligible patients.
• Most insurances accepted for qualifying medical visits.
• Self-pay GLP-1 injection options starting from $59.99/week and up when available and medically appropriate.
• Pricing, insurance coverage, medication access, and eligibility vary by patient, location, medication, pharmacy availability, and medical evaluation.

How W8MD can help

W8MD can help patients determine whether GLP-1-based treatment is appropriate and safe.

W8MD may provide:

• Physician-supervised medical weight loss
• GLP-1 medication evaluation
• Review of medical history and contraindications
• Insurance visit support
• Prior authorization support when available
• Self-pay options when available
• Nutrition planning
• Meal replacements
• Protein planning
• Side-effect management
• Weight-loss plateau support
• Sleep apnea screening
• Home sleep test when appropriate
• Zepbound evaluation for adults with obesity and moderate-to-severe OSA when appropriate
• Long-term weight maintenance

GLP-1 medications and sleep medicine

Many patients with obesity also have undiagnosed obstructive sleep apnea, which can worsen fatigue, cravings, blood pressure, insulin resistance, and difficulty losing weight. W8MD’s combined focus on medical weight loss and sleep medicine allows patients to address both conditions.

Sleep symptoms to discuss include:

• Snoring
• Daytime sleepiness
• Morning headaches
• Waking up choking or gasping
• Witnessed pauses in breathing
• Fatigue despite sleep
• High blood pressure
• Weight gain or difficulty losing weight

Why medical supervision matters

GLP-1 medications should be used with medical supervision because dosing, side effects, medication interactions, and eligibility vary by patient. Unsupervised online products may be unsafe.

Medical supervision helps with:

• Correct medication selection
• Dose escalation
• Side-effect management
• Monitoring hydration and nutrition
• Preventing excessive muscle loss
• Avoiding unsafe drug combinations
• Adjusting diabetes medications
• Monitoring blood pressure
• Long-term maintenance

Avoid unapproved GLP-1 products

Patients should avoid buying unapproved online “research” peptides, counterfeit semaglutide, counterfeit tirzepatide, or investigational products such as retatrutide sold for human use outside legitimate clinical trials. Such products may be unsafe, mislabeled, contaminated, or illegally marketed.

GLP-1 treatment and long-term maintenance

GLP-1 medications work best as part of a long-term plan. Stopping medication without a maintenance strategy may lead to weight regain in many patients.

Maintenance strategies include:

• Continued medical follow-up
• Protein-first eating
• Strength training
• Sleep apnea treatment
• Meal planning
• Weight monitoring
• Relapse prevention
• Medication continuation when appropriate
• Transition planning if medication is stopped

Frequently asked questions

Are GLP-1 medications the same as diet pills?

No. GLP-1 medications are hormone-based injectable or oral medications that affect appetite, satiety, and glucose regulation. Traditional diet pills such as phentermine work differently.

Is semaglutide the same as Wegovy?

Semaglutide is the generic active ingredient. Wegovy is the brand used for weight management. Ozempic and Rybelsus are semaglutide brands used for type 2 diabetes.

Is tirzepatide the same as Zepbound?

Tirzepatide is the generic active ingredient. Zepbound is the brand used for weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro is the diabetes brand.

Is retatrutide available now?

Retatrutide is investigational and not FDA-approved. It should not be purchased online or used outside legitimate clinical trials.

Can W8MD help with GLP-1 shots?

Yes. W8MD can evaluate patients for GLP-1 weight-loss injections when medically appropriate, help with nutrition, provide sleep apnea screening, and support long-term maintenance.

Does W8MD accept insurance?

W8MD accepts most insurances for qualifying medical visits. Affordable GLP-1 options may start at $29.99/week and up with insurance for visits for eligible patients.

What if I do not have insurance?

Self-pay GLP-1 injection options may start from $59.99/week and up when available and medically appropriate. Pricing and eligibility vary.

Can Zepbound help sleep apnea?

Yes. Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Patients may still need CPAP, APAP, BiPAP, sleep testing, lifestyle treatment, or other care depending on medical evaluation.

When to call a doctor

Seek medical advice before starting GLP-1 therapy if you have:

• Type 1 diabetes
• Type 2 diabetes using insulin or sulfonylureas
• Kidney disease
• Pancreatitis history
• Gallbladder disease
• Severe gastrointestinal disease
• Pregnancy or breastfeeding
• Eating disorder history
• Medullary thyroid cancer history
• Multiple endocrine neoplasia type 2
• Severe nausea, vomiting, dehydration, or abdominal pain

Conclusion

GLP-1 agonists and related incretin-based medications have changed the treatment of obesity, type 2 diabetes, cardiometabolic risk, and selected sleep apnea care. Medications such as semaglutide, tirzepatide, and liraglutide can help selected patients lose weight when combined with medical supervision, healthy nutrition, protein planning, physical activity, sleep optimization, and long-term maintenance. Emerging agents such as retatrutide may expand future options but remain investigational until approved. W8MD Weight Loss, Sleep and MedSpa can help eligible patients access affordable GLP-1 weight-loss care, evaluate medication options, screen for sleep apnea, and build a sustainable plan for long-term health.

See also

• GLP-1
• GLP-1 receptor agonist
• GLP-1 weight loss
• Weight loss injections
• Medical weight loss
• Semaglutide
• Wegovy
• Ozempic
• Rybelsus
• Tirzepatide
• Zepbound
• Mounjaro
• Liraglutide
• Saxenda
• Victoza
• Retatrutide
• Orforglipron
• CagriSema
• Obesity
• Overweight
• Insulin resistance
• Prediabetes
• Type 2 diabetes
• Metabolic syndrome
• Sleep apnea
• Obstructive sleep apnea
• W8MD Weight Loss, Sleep and MedSpa

Relevant WikiMD links

• Semaglutide
• Tirzepatide
• Wegovy
• Ozempic
• Zepbound
• Mounjaro
• Liraglutide
• Saxenda
• Victoza
• Retatrutide
• GLP-1
• GLP-1 receptor agonist
• Weight loss
• Medical weight loss
• Obesity
• Sleep apnea

Further reading

• FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight(link). U.S. Food and Drug Administration.March 8, 2024.
• FDA Approves First Medication for Obstructive Sleep Apnea(link). U.S. Food and Drug Administration.December 20, 2024.
• WEGOVY - semaglutide injection, solution(link). DailyMed, National Library of Medicine.
• ZEPBOUND - tirzepatide injection, solution(link). DailyMed, National Library of Medicine.
• "Triple-Hormone-Receptor Agonist Retatrutide for Obesity".New England Journal of Medicine.2023;doi:10.1056/NEJMoa2301972.PMID:37366315.

External links

• NYC medical weight loss
• Philadelphia medical weight loss
• Semaglutide on WikiMD
• Tirzepatide on WikiMD